Malvern (U.K.) Diabetic Foot Conference on May 14-16, 2014
WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that
develops wearable medical technology and point-of-care tests to help
patients and physicians manage chronic pain, nerve diseases, and sleep
disorders, reported today that it will be an exhibitor and sponsor at
the 15th Malvern Diabetic Foot Conference May 14-16, 2014 in Malvern,
United Kingdom, at the Malvern Theatres.
"We are pleased to be invited as an exhibiting sponsor to this premier
diabetes conference," said Shai N. Gozani, M.D., Ph.D., President and
Chief Executive Officer, NeuroMetrix. "This is an opportunity to
showcase our SENSUS™ device for treating chronic neuropathic pain and
our NC-stat® DPNCheck® test for detecting diabetic
peripheral neuropathy to European leaders in the care of patients with
diabetes. It may also provide insight into the European market
opportunity for our products."
The Malvern Diabetic Foot Conference is the longest-standing
international diabetic foot meeting held globally every other year. The
current conference will be the fifteenth meeting since its inception in
1986. The event brings together experts on the diabetic foot from up to
30 countries, predominantly North America and Western Europe. It
attracts physicians, surgeons, podiatrists, orthotists and nursing staff
with a common interest in diabetic foot problems with the goal of
improving the understanding in this area which represents one of the
main causes for in-patient treatment among the diabetic population. For
more information, visit http://www.malverndiabeticfoot.org/.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The Company markets
the SENSUS device for treating chronic pain, focusing on physicians
managing patients with neuropathic pain such as painful diabetic
neuropathy. The Company also markets DPNCheck, which is a rapid,
accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
